H.I.G. BioHealth Partners

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Neurana Pharmaceuticals, Inc. is a pharmaceutical company based in San Diego, California, focusing on the development of treatments for neuromuscular conditions. Founded in 2013, the company specializes in a novel therapeutic compound, Tolperisone, which addresses acute and painful muscle spasms in the neck and back as well as other musculoskeletal issues. Unlike traditional muscle relaxants, Tolperisone provides relief without causing sedation, offering a unique solution for patients experiencing spasticity and muscle discomfort.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Orbus Therapeutics, Inc. is a biopharmaceutical company based in Palo Alto, California, established in 2012. The company specializes in the development and commercialization of therapies aimed at treating brain cancers and other rare diseases. Its primary product, Eflornithine, is an orally bioavailable small molecule that acts as a cytostatic agent, specifically targeting recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. Orbus Therapeutics is dedicated to improving health outcomes for patients with life-threatening conditions by developing innovative medicinal products that inhibit tumor growth through the irreversible inhibition of the enzyme ornithine decarboxylase (ODC). The company is actively working on bringing Eflornithine to the North American market.

RxSight, Inc. is a medical technology company focused on enhancing vision outcomes for patients after cataract surgery. Based in Aliso Viejo, California, the company develops the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL) and the Light Delivery Device (LDD). This innovative system allows surgeons to customize and optimize patients' visual acuity post-surgery, making it the first commercially available intraocular lens technology that enables such personalization. The LAL incorporates ActivShield™ technology, a unique UV protection layer that further enhances its functionality. Founded in 1997 and originally known as Calhoun Vision, RxSight changed its name in 2017 to reflect its commitment to advancing ophthalmic care through precision lens technology.

RxSight, Inc. is a medical technology company focused on enhancing vision outcomes for patients after cataract surgery. Based in Aliso Viejo, California, the company develops the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL) and the Light Delivery Device (LDD). This innovative system allows surgeons to customize and optimize patients' visual acuity post-surgery, making it the first commercially available intraocular lens technology that enables such personalization. The LAL incorporates ActivShield™ technology, a unique UV protection layer that further enhances its functionality. Founded in 1997 and originally known as Calhoun Vision, RxSight changed its name in 2017 to reflect its commitment to advancing ophthalmic care through precision lens technology.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Cardeas Pharma is focused on developing a novel antibiotic formulation that combines two drugs to effectively target highly resistant Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is also effective against biofilms and Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The antibiotics are delivered through a single-patient use nebulizer that produces small, uniform aerosol droplets, allowing for targeted delivery to the small airways and alveoli. By integrating this innovative antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to improve clinical outcomes for patients suffering from serious, hospital-acquired respiratory infections.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in developing innovative drug delivery technologies aimed at treating various eye conditions. The company focuses on creating non-invasive products designed to replace traditional eye drops, offering sustained therapy for significant eye diseases such as glaucoma, dry eye, and allergies. Currently, ForSight VISION5 is in its second Phase 2 clinical study for its lead product, the Helios insert, which represents a significant advancement in ocular treatment options.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

ForSight Labs is dedicated to developing innovative ophthalmic technologies aimed at enhancing the sight and quality of life for visually impaired patients. The organization collaborates with entrepreneurs, investors, and clinicians to drive advancements in eye care through the creation and commercialization of high-impact solutions. With millions of individuals in the U.S. suffering from vision impairment and the associated economic burden exceeding $50 billion annually, ForSight Labs addresses a significant public health challenge. Their focus includes developing treatments for conditions such as glaucoma, which can lead to irreversible blindness in adults. By fostering a creative and cooperative environment, ForSight Labs strives to deliver effective solutions to the ophthalmic community and the patients it serves.

Cerephex Corporation develops non-invasive treatment and diagnostic technologies for chronic centralized pain conditions, specifically focusing on fibromyalgia. The company's flagship product, NeuroPoint, is a point-of-care medical device utilizing proprietary RINCE technology, which employs noninvasive cortical electrostimulation to target and modulate brain function. This device aims to address the abnormal pain processing mechanisms associated with fibromyalgia. Cerephex is actively working towards obtaining FDA approval for NeuroPoint, enabling its use in clinical outpatient settings under physician supervision. Founded in 2012 and based in Los Altos, California, Cerephex was previously known as Great Lakes BioSciences.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.